Obocell
Obocell is the brand name of a CNS stimulant and appetite suppressant combined into one pill with a CNS depressant and first generation antihistamine. This combination formula was developed by Neisler Laboratories in 1951, approved for medical use in the United States by the U.S. Food and Drug Administration in 1953 to treat obesity.
According to the National Institutes of Health, production or availability of Obocell was discontinued around 1967. It was approved for medical use in the U.S. in 1953, and available for over the counter sales between 1953 and 1967, in the dosage form of a tablet, and indicated for treating obesity in patients by functioning as an appetite suppressant.
Indication and use
Obocell's formulation of active ingredients included a substituted amphetamine produced as a single tablet containing the 5mg:25mg dosage ratio, directed for oral consumption. A similar, yet distinct, product was marketed by Irwin, Neisler & Co. called Obocell-TF, which also included a ratio of 5mg dextroamphetamine phosphate and 25mg methapyrilene, with an additional component being Irwin, Neisler & Co.'s high-viscosity methylcellulose product.Treatment indication and medical use
Both formulations were FDA-approved in the United States as treatments of obesity. Full therapeutic effect as an appetite suppressant was achieved by consuming the medication thirty to sixty minutes prior to each meal. The manufacturer-recommended dosage was one or two tablets, to be taken with a full glass of water three times daily. Nitrin provided additional benefits, such as cardioprotective antioxidants and contributed dietary fiber. Obocell-TF with methylcellulose had the added benefit of protecting cardiovascular health and reducing constipation.Both medications have since been discontinued, although the exact year has not yet been identified.